Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLYCD | O95822 | 9/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | CES2 | O00748 | 1/20 | 0.40 |
| ▸ | CES1 | P23141 | 1/20 | 0.40 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.39 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.39 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6229257 | 0.83 | MLYCD (0.54) | MLYCDTSHRHTTSERPINE1ALDH1A1 | |
| SCHEMBL29239542 | 0.79 | ALDH1A1 (0.46) | TSHRALDH1A1GLA | |
| SCHEMBL24795106 | 0.79 | MLYCD (0.49) | MLYCDTSHRHTTALDH1A1GLA | |
| SCHEMBL3419287 | 0.77 | MEN1 (0.38) | MLYCDHTTALDH1A1HDAC6CES2 | |
| SCHEMBL3647451 | 0.72 | UTS2R (0.39) | SERPINE1ALDH1A1HDAC6HDAC8 | |
| SCHEMBL3422810 | 0.72 | KDM2B (0.45) | MLYCD | |
| SCHEMBL12638465 | 0.72 | HDAC6 (0.45) | MLYCDSERPINE1ALDH1A1HDAC6CES2 | |
| SCHEMBL4290193 | 0.71 | HDAC8 (0.49) | MLYCDTSHRALDH1A1GLAHDAC8 | |
| SCHEMBL6521921 | 0.71 | HTR2C (0.43) | MLYCD | |
| SCHEMBL4044376 | 0.70 | CES2 (0.44) | MLYCDSERPINE1CES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100216749-A1 | Combination Therapy for Neuroprotection | S.H. PHARMA., LTD (KR) | 2010-08-26 | — | — | US | claimed |
| US-20100216749-A1 | Combination Therapy for Neuroprotection | S.H. PHARMA., LTD (KR) | 2010-08-26 | — | — | US | disclosed |
| WO-2009045083-A2 | COMBINATION THERAPY FOR NEUROPROTECTION | S.H. PHARMA., LTD (KR) | 2009-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216749-A1 | Combination Therapy for Neuroprotection | MPO, BDNF, NLN | MLYCD 674/4885TSHR 4770/4885HTT 849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.